Lilly Q4 2021 non-GAAP EPS $2.49 (+8%), revenue $8.0B +8%; 2022 guidance reaffirmed

ELI LILLY & Co

2021-FY EPS reported $6.12 revenue$28,318,400,000

Q4 revenue $7,999.9M (+8% YoY); non-GAAP EPS $2.49 (+8%).
Full-year revenue $28,318.4M (+15%); non-GAAP EPS $8.16 (+20%).
COVID-19 antibody revenue $1.06B in Q4, $2.24B for full year.
Key growth products (Trulicity, Taltz, Verzenio, Jardiance, Olumiant) contributed 14 ppt revenue growth ex-COVID.
2022 EPS guidance: GAAP $8.00-$8.15, non-GAAP $8.50-$8.65; dividend raised 15%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.